Top Forestry Stocks To Invest In 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What:�Shares of Capstone Turbine (NASDAQ: CPST  ) skyrocketed 13.59% as the company announced that it had signed a major supplier deal with private real estate and investment firm Related Companies. Shares of Capstone haven't been this high in over a year.

So what: No details regarding dollars were given in the announcement, but the deal is set to include several of Capstone's C65 and C200 Dual Mode microturbines over the next couple of years. This deal could also hint at a long-term relationship, as Related has stated it has commited to spending $10 billion in sustainable building designs. Hopefully, this will help Capstone in its long march toward profitability.�

Top Forestry Stocks To Invest In 2014: Electrocomponents(ECM.L)

Electrocomponents plc distributes electronics and maintenance products to engineers in the United Kingdom, rest of continental Europe, North America, and the Asia Pacific. It offers electronics, electrical, industrial, and commercial supplies and services primarily under the RS brand, as well as under the Allied brand. The company sells its products through catalogues, trade counters, third party distributors, and ecommerce operations, as well as trading Web sites serving electronics and maintenance engineers. Electrocomponents plc was founded in 1937 and is based in Oxford, the United Kingdom.

Top Forestry Stocks To Invest In 2014: Patterson Companies Inc.(PDCO)

Patterson Companies, Inc. operates as a distributor serving the dental, companion-pet veterinarian, and rehabilitation supply markets in North America. Its Dental Supply segment provides consumable dental supplies, such as x-ray film and solutions; impression and restorative materials; hand instruments; sterilization products; anesthetics; infection control products, including protective clothing, gloves, and facemasks; paper, cotton, and disposable products; toothbrushes; dental accessories; printed office products, office filing supplies, and practice management systems; x-ray machines, handpieces, dental chairs and handpiece control units, diagnostic equipment, dental lights, compressors, chair-side restoration systems, and inter-oral cameras; practice management and clinical software; hardware and networking solutions; and patient education solutions. The company?s Veterinary Supply segment offers consumable supplies, such as lab supplies, paper goods, needles and syr inges, gauze and wound dressings, sutures, latex gloves, and orthopedic and casting products; pharmaceuticals comprising anesthetics, antibiotics, ointments, and nutraceuticals; diagnostics; biologicals, including vaccines and injectibles; and equipment and software. Its Rehabilitation Supply segment provides dressing and grooming devices, and toileting, dining, and bathing aids; braces, splints, and orthotics; exercise bands, putty, weight balls, and mats; walkers, canes, and wheelchair accessories; rolls, wedges, seating and standers, and mobility assistance products; motor stimulation products; products for heating and cooling therapies, electrical stimulation, laser, ultrasound, paraffin, iontophoresis, and therapeutic creams and lotions; and rehabilitation equipment and software. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is based in St. Paul , Minnesota.

Top Casino Companies To Invest In 2014: Diageo plc(DEO)

Diageo plc engages in producing, distilling, brewing, bottling, packaging, distributing, developing, and marketing spirits, beer, and wine products worldwide. It offers a range of brands, including Johnnie Walker scotch whiskies, Smirnoff vodka and Smirnoff ready to drink products, Baileys Original Irish Cream liqueur, Crown Royal Canadian whisky, Captain Morgan rum and rum based products, Jose Cuervo tequila, JeB scotch whisky, Buchanan?s scotch whisky, Windsor Premier scotch whisky, Ketel One vodka, Ciroc vodka, Tanqueray gin, Bushmills Irish whiskey, and Guinness stout. The company also provides other spirits brands that comprise Gordon?s gin and vodka, Old Parr scotch whisky, Bell?s scotch whisky, The Classic Malts scotch whiskies, Seagram?s 7 Crown whiskey and Seagram?s VO whisky, Cacique rum, White Horse scotch whisky, Don Julio tequila, and Bundaberg rum. In addition, it offers beer under various brands, such as Malta Guinness non-alcoholic malt, Harp lager, Tu sker lager, Smithwick?s ale, Senator lager, and Red Stripe lager; and wine under a range of brands, including Blossom Hill, Sterling Vineyards, Beaulieu Vineyard, Navarro Correas, Acacia Vineyard, Rosenblum Cellars, Piat d?Or, Chalone Vineyard, and Santa Rita. Further, Diageo plc owns the distribution rights for the Jose Cuervo tequila brands in North America and internationally. The company was founded in 1886 and is based in London, the United Kingdom.

Advisors' Opinion:

• [By Richard Young]

  Diageo has had great success in Africa and is replicating that success in South America. In Brazil, nine out of 10 shots of Scotch served are Diageo’s brands. Fifty percent of Scotch served in Venezuela is Diageo’s. The potential in South America is attractive. Between 10 million and 15 million people are entering the middle class in Latin America every year. My relative strength chart for Diageo has reached a five-year high.

Top Forestry Stocks To Invest In 2014: National Beverage Corp.(FIZZ)

National Beverage Corp., together with its subsidiaries, develops, manufactures, markets, and distributes beverage products in the United States. The company offers a range of flavored soft drinks, juices, sparkling waters, energy drinks, and nutritionally-enhanced waters. It provides its soft drink products under the Shasta and Faygo names. The company also provides health-conscious beverage products, including juice and juice based products under the Everfresh, Home Juice, and Mr. Pure brand names; sparkling and spring water products under the LaCroix, Crystal Bay, and ClearFruit brand names; and nutritionally enhanced water under the Asante brand. In addition, it offers energy drinks under the brand, Rip It; fruit-flavored drinks under the Ohana brand name; holiday soft drinks under the brand, St. Nick?s; and effervescent powder beverage enhancers under the NutraFizz brand name. Further, the company develops and produces soft drinks for retailers and beverage companies . National Beverage provides its products through national and regional grocery stores, warehouse clubs, mass-merchandisers, wholesalers and dollar stores, convenience stores, gas stations, and independent and specialized distributors, as well as through direct store distribution facilities. The company was founded in 1985 and is based in Fort Lauderdale, Florida.

Top Forestry Stocks To Invest In 2014: Loral Space and Communications Inc.(LORL)

Loral Space & Communications Inc. operates as a satellite communications company. The company?s Satellite Manufacturing segment designs and manufactures satellites, space systems, and components used for fixed satellite services, direct-to-home (DTH) broadcasting, mobile satellite services, broadband data distribution, wireless telephony, digital radio, digital mobile broadcasting, military communications, weather monitoring, and air traffic management applications in commercial and government sectors. Loral Space & Communications Inc.?s Satellite Services segment provides broadcast, enterprise, and consulting services. This segment owns and leases a satellite fleet that provides high-bandwidth services to broadcasters, cable networks, and DTH service providers. It also offers satellite transmission services for the broadcast of news, sports, and live events coverage enabling broadcasters to conduct on-the-scene transmissions. In addition, this segment operates very smal l aperture terminal (VSAT) networks in North America, and manages various VSAT terminals at customer sites, as well as provides the installation and maintenance of the end user terminal, the VSAT hub, and satellite capacity services. Further, it offers Internet protocol-based terrestrial extension services; Ka-band two-way broadband Internet services; satellite capacity and end-to-end services for data and voice transmission to telecommunications carriers; fixed satellite services to the United States and Canadian governments; and satellite consulting services. The company also owns and operates an X-band satellite, which provides X-band communications services to government users. As of December 31, 2011, it had 12 in-orbit satellites and 2 satellites under construction. The company operates in the United States, Canada, Europe, the Middle East, Africa, Asia, Australia, Latin America, and Caribbean. Loral Space & Communications Inc. was founded in 1996 and is headquartered in New York, New York.

Top Forestry Stocks To Invest In 2014: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.